Thione-platinum(II) complexes and pharmaceutical compositions thereof

Patent metadata

Field	Value
Publication number	US-9840528-B2
Application number	US-201615282014-A
Country	US
Kind code	B2
Filing date	Sep 30, 2016
Priority date	Sep 15, 2015
Publication date	Dec 12, 2017
Grant date	Dec 12, 2017

Abstract

Platinum(II) complexes having thione-based heterocyclic ligands as anticancer agents. The central platinum atom is coordinated by four of the ligands, each having a five-, six- or seven-membered heterocyclic ring with two nitrogen atoms at positions 1 and 3 of the ring and a thiocarbonyl group at position 2. Pharmaceutical compositions incorporated the platinum(II) complexes, methods of synthesizing the complexes and methods of treating cancers with the complexes or pharmaceutical compositions thereof are also described.

First claim

The invention claimed is:

1. A platinum(II) complex of Formula I:

or a pharmaceutically acceptable salt, tautomer, ester, solvate or prodrug thereof;
wherein:
R 1 , R 3 , R 5 , and R 7 are each independently a hydrogen atom, and R 2 , R 4 , R 6 , and R 8 are each independently a C 1 -C 3 alkyl group, and
R 25 -R 31 are each independently a hydrogen atom, a halogen atom, an optionally substituted C 1 -C 8 alkyl group, an optionally substituted C 1 -C 8 alkoxy group, an optionally substituted C 2 -C 8 alkenyl group or an optionally substituted C 2 -C 8 alkynyl group.

2. The platinum(II) complex of claim 1 , wherein
R 2 , R 4 , R 6 , and R 8 , are each a methyl group, an ethyl group, a propyl group or an isopropyl group;
and
R 25 -R 31 are each a hydrogen atom.

3. The platinum(II) complex of claim 1 , further comprising one or more pharmaceutically acceptable anions.

4. The platinum(II) complex of claim 2 , wherein the one or more pharmaceutically acceptable anions are chloride and nitrate.

5. A pharmaceutical composition, comprising:
the platinum(II) complex of claim 1 or a pharmaceutically acceptable salt, tautomer, ester, solvate or prodrug thereof; and
one or more pharmaceutically acceptable carriers.

6. The pharmaceutical composition of claim 5 , further comprising one or more other active pharmaceutical agents.

7. The pharmaceutical composition of claim 5 , further comprising one or more non-active ingredients.

Assignees

• Univ King Fahd Pet & Minerals

Inventors

• Altaf Muhammad
• Isab Anvarhusein Abdulkadir

Classifications

• A61K31/555

  containing heavy metals, e.g. hemin, hematin, melarsoprol · CPC title

• C07F15/0093 Primary

  without a metal-carbon linkage · CPC title

• A61K31/282

  Platinum compounds · CPC title